Replimune Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 206

Employees
  • Stock Symbol
  • REPL

Stock Symbol
  • Share Price
  • $17.48

  • (As of Thursday Closing)

Replimune General Information

Description

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • 18 Commerce Way
  • Woburn, MA 01801
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Replimune Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.48 $17.45 $13.05 - $40.12 $858M 49.1M 377K -$2.26

Replimune Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021 FY 2020 31-Mar-2020
EV 414,543 414,543 958,663 226,523
Revenue 0 0 0 0
EBITDA (113,666) (113,666) (76,099) (50,173)
Net Income (118,036) (118,036) (80,870) (52,625)
Total Assets 461,192 461,192 543,098 234,097
Total Debt 32,839 32,839 33,280 41,789
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Replimune Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Replimune‘s full profile, request access.

Request a free trial

Replimune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Replimune‘s full profile, request access.

Request a free trial

Replimune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop
Biotechnology
Woburn, MA
206 As of 2022
00000
0000 0000-00-00
00000000 00000

000000

dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore ma
0000000000000
Dallas, TX
000 As of 0000
00000
00000000 00000

000000

lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
0000000000000
Cambridge, MA
000 As of 0000
00000
000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Replimune Competitors (71)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Instil Bio Formerly VC-backed Dallas, TX 000 00000 00000000 00000
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000
0000 000000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 71 competitors. Get the full list »

Replimune Patents

Replimune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201700350-D0 Altered virus Ceased 09-Jan-2017 0000000000
CA-3049496-A1 Altered virus Pending 09-Jan-2017 0000000000
EP-3565568-A1 Altered virus Pending 09-Jan-2017 0000000000
US-20190343903-A1 Altered virus Pending 09-Jan-2017 0000000000
JP-2020503871-A Modified virus Pending 09-Jan-2017 C07K16/2818 0
To view Replimune’s complete patent history, request access »

Replimune Executive Team (14)

Name Title Board Seat Contact Info
Philip Astley-Sparke Chief Executive Officer & Founder
Jean Franchi Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Colin Love Chief Operating Officer, Operations
Pamela Esposito Ph.D Executive
Sushil Patel Executive
You’re viewing 5 of 14 executive team members. Get the full list »

Replimune Board Members (12)

Name Representing Role Since
Dieter Weinand Self Chairman & Board Member 000 0000
Hyam Levistsky Self Board Member 000 0000
Hyam Levitsky MD Self Board Member 000 0000
Jason Rhodes Atlas Venture Board Member 000 0000
Joseph Slattery Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Replimune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Replimune Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Replimune‘s full profile, request access.

Request a free trial